

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68, C12N 15/62		A1	(11) International Publication Number: WO 98/37235 (43) International Publication Date: 27 August 1998 (27.08.98)
(21) International Application Number: PCT/US98/00023 (22) International Filing Date: 12 January 1998 (12.01.98) (30) Priority Data: 60/038,254 24 February 1997 (24.02.97) US (71) Applicants (for all designated States except US): CORNELL RESEARCH FOUNDATION, INC. [US/US]; Suite 105, 20 Thornwood Drive, Ithaca, NY 14850 (US). THE UNIVERSITY OF MISSISSIPPI [US/US]; 125 Old Chemistry, University, MS 38677 (US). (72) Inventors: and (75) Inventors/Applicants (for US only): DANNENBERG, Andrew, J. [US/US]; Apartment 14A, 7 Gracie Square, New York, NY 10028 (US). SUBBARAMAIAH, Kotha, J. [IN/US]; Apartment 17K, 43-23 Colden Street, Flushing, NY 11355 (US). PASCO, David, S. [US/US]; 706 Oakhill Drive, Oxford, MS 38655 (US). (74) Agent: SPECTOR, Eric, S.; Jones, Tullar & Cooper, P.C., P.O. Box 2266 Eads Station, Arlington, VA 22202 (US).		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU. ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. With amended claims and statement.	
(54) Title: METHOD OF SCREENING AGENTS AS CANDIDATES FOR DRUGS OR SOURCES OF DRUGS			
(57) Abstract Cells are transfected with a construct containing transcriptional promoter element(s) that have been implicated in carcinogenesis or inflammation ligated to a reporter gene. Determination of inhibition of activation of said promoter element(s) by putative agent indicates the agent is a candidate as a drug or source of a drug for prophylaxis or treatment of cancer or inflammation. The method has particular application to screening agents as candidates for drugs or sources of drugs for prophylaxis or treatment of human disorders caused or mediated by cyclooxygenase-2 and/or matrix metalloproteinases.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD OF SCREENING AGENTS AS CANDIDATES FOR
DRUGS OR SOURCES OF DRUGS

This invention was made at least in part with Government support under grant CA68136 from the National Cancer Institute. Therefore, the Government has certain rights in the invention.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 60/038,254, filed February 24, 1997.

TECHNICAL FIELD

This invention is directed to a method of screening agents for potential as drugs or sources of drugs, and especially for screening agents for potential as drugs for disorders caused or mediated by the expression of genes involved in inflammation and/or carcinogenesis.

BACKGROUND OF THE INVENTION

There is strong evidence that cyclooxygenase-2 (COX-2) is important in carcinogenesis and that inhibition of COX-2 protects against tumor formation. Moreover, COX-2 is known to be associated with inflammatory responses incident to a number of disorders, and major pharmaceutical companies are actively involved in the development of selective COX-2 inhibitors to treat inflammation.

There is also strong evidence that matrix metalloproteinases are associated with carcinogenesis and inflammation and are involved in tumor metastasis. The term "matrix

metalloproteinase" is referred to hereinafter as "MMP".

One of the limitations of drug discovery is the time and expense involved in identifying candidate compounds. There is, at present, no rapid and easy method for identifying sources of novel anti-cancer compounds and/or anti-inflammatory compounds.

SUMMARY OF THE INVENTION

It has been discovered herein that determining whether an agent suppresses the stimulation of a gene promoter that has been implicated in carcinogenesis, or inflammation, is an effective tool for screening agents as candidates for preventing or treating cancer and/or inflammation.

The invention herein relying on this discovery, is directed at a method for screening agents as candidates for prophylaxis or treatment of cancer or inflammation. The method relies on cells that are transfected with a construct containing transcriptional promoter element(s) that have been implicated in carcinogenesis or inflammation ligated to a reporter gene. Determination in the method, of inhibition of activation of said transcriptional promoter element(s) by agent which is being screened, indicates the agent is a candidate as a drug or source of a drug for prophylaxis or treatment of cancer or inflammation. Thus, a method herein is directed to screening agents as candidates for prophylaxis or treatment of cancer or inflammation and comprises (a) providing cells that are transfected with a construct containing transcriptional promoter element(s) that have been implicated in carcinogenesis or inflammation

ligated to a reporter gene, and (b) determining whether putative agent inhibits activation of said transcriptional promoter element(s) with a determination of inhibition indicating that the putative agent is a candidate as a drug or as a source of a drug for prophylaxis or treatment of cancer or inflammation. The method has particular application to screening agents as candidates for drugs for prophylaxis or treatment of mammalian (e.g., human) disorders caused or mediated by cyclooxygenase-2. In this case, putative therapeutic agents are investigated for their ability to suppress stimulation of cyclooxygenase-2 promoter activity by exogenous stimulus. The method also has particular application to screening agents as candidates for drugs for prophylaxis or treatment of mammalian (e.g., human) disorders caused or mediated by MMPs. In this case, putative therapeutic agents are investigated for their ability to suppress stimulation of MMP promoter activity by exogenous stimulus.

There are a plurality of transcriptional promoter elements in cyclooxygenase-2 and in other genes, e.g., the Phorbol Ester Responsive Element (TRE), Nuclear Factor- κ B (NF- κ B) and a cyclic AMP response element (CRE), that have been implicated in carcinogenesis and in inflammatory response. In one embodiment of the invention herein, a battery of screenings are carried out on a putative agent utilizing in each case cells transfected with a different construct and/or transfected cells activated with a different activator. In the method of this embodiment, both specificity or sensitivity (where the putative agent inhibits one or less than all the transcriptional promoter elements) and breadth of activity are determined. The more different transcriptional promoter

elements a putative agent inhibits and the more different activators a putative agent suppresses, the greater the likelihood is that the agent is an effective drug or the source of an effective drug for the prevention or treatment of cancer and/or inflammation. This embodiment increases the predictive value of the method herein.

As used herein, the term "transcriptional promoter element(s) that have been implicated in carcinogenesis or inflammation" means element(s) that mediate the transactivation function of transcription factors that control expression of the COX-2 gene or members of the MMP gene family.

As used herein the term "MMP gene family" and "MMP" includes genes that express collagenase(s), genes that express gelatinase(s), genes that express elastin, genes that express stromelysins, and other genes that express matrix metalloproteinases.

BRIEF DESCRIPTION OF THE DRAWINGS

Figs. 1a-1f each depict bar graphs showing inhibition results in terms of light units from luciferase activity where different construct/activator combinations are used in testing on four plant extracts as described in Example II.

Figs. 2a-2f each depict bar graphs showing inhibition results in terms of light units from luciferase activity where different construct/activator combinations are used in testing on shikonin as described in Example II.

DETAILED DESCRIPTION

We turn now to the method herein for screening agents as candidates for drugs for prophylaxis or treatment of mammalian disorders caused or mediated

by cyclooxygenase-2 expression. Cells transfected with a construct comprising a 5'-flanking region of the human cyclooxygenase-2 gene or equivalent thereof, e.g., synthetic equivalent thereof, or other transcriptional promoter element of the human cyclooxygenase-2 gene ligated to a reporter gene are treated with an activator of cyclooxygenase-2 promoter activity. The agent being screened is tested for its ability to suppress stimulation of the cyclooxygenase-2 promoter. The agent is a candidate as a drug or source of a drug for prophylaxis or treatment of mammalian disorders caused or mediated by cyclooxygenase-2 expression if stimulated promoter activity is reduced by the agent.

We turn now to the method herein for screening agents as candidates for drugs for prophylaxis or treatment of mammalian disorders caused or mediated by MMP expression. Cells transfected with a construct containing a transcriptional promoter element from the human stromelysin gene or equivalent thereof, e.g., synthetic equivalent thereof, or from other MMP gene, or equivalent thereof, e.g., synthetic equivalent thereof, ligated to a reporter gene are treated respectively with an activator of stromelysin or other MMP promoter activity. The agent being screened is tested for its ability to suppress stimulation of the promoter. The agent is a candidate as a drug or source of a drug for prophylaxis or treatment of mammalian disorders caused or mediated by MMP expression if stimulated promoter activity is reduced by the agent.

Where an agent is determined to inhibit stimulation of both cyclooxygenase-2 promoter and also MMP promoter, this indicates a higher

likelihood of anticancer or antiinflammatory property than inhibition in only one of the cases.

We turn now to the transcriptional elements of the constructs.

The sequence of the human cyclooxygenase-2 gene is described in Kosaka, T., et al., Eur. J. Biochem. 221, 889-897 (1994) which is incorporated herein by reference.

The region of human cyclooxygenase-2 gene constituting said 5'-flanking region may contain, for example, 1475 bases 5' of the cyclooxygenase-2 transcription start site having, for example, the sequence -1475/+59, or 1432 bases 5' of the cyclooxygenase-2 transcription start site having, for example, the sequence -1432/+59 or 375 bases 5' of the cyclooxygenase-2 transcription start site having, for example, the sequence -375/+59, or 327 bases 5' of the cyclooxygenase-2 transcription start site having, for example, the sequence -327/+59. Other transcriptional promoter elements of the cyclooxygenase-2 gene, for use herein, for forming said construct include, for example, the cyclic AMP response element (-59/-53), the NF- κ B element (-223/-214), and the NFIL-6 element (-132/-124). Synthetic promoter elements such as synthetic NF- κ B may be used in place of a promoter element from the cyclooxygenase gene, for example, the NF- κ B motif from HIV/IgK which is described in Chang, C. C., et al., Oncogene 9(3), 923-933 (1994) which is incorporated herein by reference. The specific sequence actually used for NF- κ B in Example II hereinafter is that set forth in Table 1 of Chang et al. for the μ IgK gene but the sequence set forth for NF- κ B in said Table 1 for the HIV gene is equivalent. The term "HIV/IgK" is used herein in relation to NF- κ B as indicating the

equivalence of the NF- κ B sequences for mu IgK and HIV.

The sequence of the human stromelysin gene is described in Quinones, S., et al., J. Biol. Chem. 264 (14), 8339-8344 (1989) which is incorporated herein by reference. The transcriptional promoter elements thereof are known and include the region -1303 to -11 relative to the transcription start site. A synthetic transcriptional promoter element for the human stromelysin gene is denoted herein as Ets2/AP-1 and consists of one copy of an inverted repeat of an Ets motif found in the stromelysin promoter which binds the Ets2 homodimer (described in Yang, B.-S., et al., Molecular and Cellular Biology, 2/96, pages 538-547 which is incorporated here by reference) and two synthetic copies of an AP-1 binding motif (having the sequence TGAGTCA) which is positioned 3' to the Ets sites. The AP-1 site sequence from the stromelysin promoter is given in Buttice, G., et al., Nucleic Acids Research, Vol. 19, No. 13, 3723-3731 (1991) which is incorporated herein by reference. The synthetic transcriptional promoter element based on the NF- κ B motif described above in conjunction with the COX-2 gene is also a synthetic transcriptional promoter element for some MMP genes.

The preferred reporter gene to which a promoter element is ligated is luciferase as described in Inoue, H., et al., FEBS Lett., 350, 51-54 (1994). Other reporter genes for use for this purpose include, for example, β -galactosidase gene (β gal) and chloramphenicol acetyltransferase gene (CAT). Assays for expression produced in conjunction with each of these reporter gene elements are well-known to those skilled in the art. An assay in connection with the luciferase

gene and an assay in connection with the β gal gene are described in Example I hereinafter.

Constructs are prepared by ligating transcriptional promoter elements to the reporter genes by methods well-known in the art, e.g., by utilizing restriction enzymes to cut the reporter gene in appropriate portion to provide binding sites for the transcriptional promoter elements, incubating the restriction enzyme treated reporter gene with the transcriptional promoter elements and screening for the recombinants. Formation of construct of COX-2 transcription start site (-1432/+59) ligated to luciferase gene is described in Inoue, H., et al., FEBS Lett., 350, 50-54 (1994) which is incorporated herein by reference.

Cell lines for transfection to provide cells transfected with construct for use herein include cells involved in carcinogenesis or inflammation. Examples of cell lines for transfection to provide cells transfected with construct for use in the method herein include, for example, 1483 squamous carcinoma cells as described in Sacks, P. G., et al., Cancer Res. 48, 2858-2866 (1988) which is incorporated herein by reference; and human chondrocyte cell line SW1353 having accession no. ATCC HTB 94 and available from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852.

Either transient systems or stably transfected cell lines can be used.

Transfection to provide a transient system can be carried out using pFx-3 as described in Example I hereinafter. In this case, standardization can be obtained by co-transfecting a plasmid which expresses β -galactosidase, e.g., pCMV.SPORT β gal, as described in Example I hereinafter. Thus, when cyclooxygenase-2-luciferase and pCMV.SPORT β gal are

co-transfected, the luciferase values obtained in the assay can be normalized using β -galactosidase activity.

A preferred method of transfection to provide a transient system involves utilizing electroporation, very preferably square wave electroporation. The electroporation causes temporary openings in the cells whereby the construct can enter inside the cell. This method can be carried out in any cell culture medium and very preferably is carried out in DME/F12 cell culture medium. As used herein, the term "DME/F12" means a 1:1 mixture of Dulbecco's Modified Eagle's Medium and Ham's Nutrient Mixture F12. The DME/F12 medium is available as product #56498 from JRH Biosciences of Lenexa, KS. The contents of the medium is set forth on page 39 of Catalog #0195 of JRH Biosciences, which is incorporated herein by reference. Very preferably the cell culture medium is supplemented with from 2 to 10% by volume of fetal bovine serum; the fetal bovine serum causes increase in survivability of cells subjected to electroporation in the transfection method, so a lower cell density can be used during electroporation to obtain the same result compared to when the fetal bovine serum is not present. In a preferred electroporation method, there are employed 500 μ l transfection medium, from 6×10^6 to 20×10^6 cells and 25 μ g of construct. A convenient electroporation time is 70 milliseconds. The voltage used will vary, e.g., from 110 volts to 200 volts, depending on the cell line and construct. A preferred voltage for a particular cell line and construct may be determined by preparing a plurality of cuvettes with the same amount of cells and DNA and utilizing a different voltage for each cuvette, e.g., 100 volts for one cuvette, 120 volts

for another cuvette, 130 volts for another cuvette, etc., and subsequently using that voltage for the same cells and construct that is determined to provide the best yield. In a very preferred method, a single electroporation is utilized to transfect cells which are subsequently diluted with additional cell culture medium to a volume such as to provide aliquots thereof of the same composition for a plurality of wells, e.g., 96 wells, for use for determinations, to provide a high throughput system and standardization without the need to use a standardizing plasmid.

For transient systems, the results need to be compared to what occurs when the method is carried out in the absence of putative agent.

Transfection to provide a stable system, i.e., a stably transfected cell line, is obtained by standard methods.

It is preferred to compare results with those obtained for agent of known effect, for example, all-trans retinoic acid which is tested in Example I below.

The activator can be any substance which is known to stimulate transcription. Such activators include, for example, tumor promoters such as phorbol esters (e.g., phorbol myristate acetate, e.g., phorbol 12-myristate 13-acetate), serum (e.g., fetal bovine serum), cytokines (e.g., tumor necrosis factor or interleukin-1), growth factors (e.g., epidermal growth factor which may be referred to as EGF), benzo[a]pyrene, lipopolysaccharide, bile acids (e.g., chenodeoxycholate and deoxycholate), free radical producing compounds such as hydrogen peroxide and cyclic AMP generating agents such as forskolin. The particular activators utilized will depend on the transcriptional promoter element in the

construct. For the broad and medium cyclooxygenase-2 promoter regions (-1475/+59, -1432/+59, -375/+59, and -327/+59), phorbol esters and epidermal growth factor are useful as activators. For cyclic AMP response elements, cyclic AMP generating agents are useful as activators. For NF- κ B elements, free radical producing agents, phorbol esters and cytokines are useful activators. For the Ets2/AP-1 promoter, phorbol esters are useful as activators.

The agent to be screened is one whose therapeutic properties are unknown for the use being screened for and can be, for example, extracts from natural products such as plant or marine organisms, compounds purified from natural products, and synthetic compounds. Automating the method herein allows large numbers of potential medicinal agents to be screened by the method herein.

All-trans retinoic acid suppresses phorbol ester induction of cyclooxygenase-2 gene promoter activity in 1483 squamous carcinoma cells. This result is obtained when transient transfections are performed using a human COX-2 promoter construct containing 1432 bases of 5'-flanking region DNA ligated to luciferase. This result demonstrates the feasibility of using retinoids to down-regulate phorbol ester mediated induction of cyclooxygenase-2 by suppressing transcription as discussed in Mestre, J. R., et al., "Retinoids Suppress Phorbol Ester-Mediated Induction of Cyclooxygenase-2", Cancer Res. 57, 1081-1085 (1997) which is incorporated herein by reference.

In the method herein, the transfected cells are preferably treated with agent being screened prior to being exposed to the activator, i.e., pretreatment. Good results are also obtained when

the activator and agent being screened are given simultaneously.

We turn now to the embodiment of the invention where a battery of screenings are carried out on a putative agent utilizing in each case cells transfected with a different construct and/or transfected cells activated with a different activator. For example, the constructs can be TRE-luciferase and NF- κ B-luciferase activated respectively by phorbol ester and lipopolysaccharide. Inhibition by putative anticancer or antiinflammatory agent of activation in each case would be determined. Inhibition in all cases indicates higher likelihood of anticancer or antiinflammatory property than inhibition in a single case.

In a very preferred method herein for screening for candidates for treatment of an inflammatory and/or carcinogenic disorder, the cells that are transfected are chondrocytes and a battery of screenings are carried out on each putative compound, where in one case the chondrocytes are transfected with a construct containing the COX-2 promoter and the activator is phorbol myristate acetate used in combination with interleukin-1; in another case, the chondrocytes are transfected with Ets2/AP-1 transcription promoter elements and the activator used is phorbol myristate acetate; in another case, the chondrocytes are transfected with construct containing NF- κ B transcription promoter element (a synthetic element containing the NF- κ B motif from HIV/1) and the activator is interleukin-1; in another case, the chondrocytes are transfected with construct containing said NF- κ B transcription promoter element and the activator is tumor necrosis factor-alpha; and in another case, the

chondrocytes are transfected with construct containing said NF- κ B transcription promoter element and the activator is phorbol myristate acetate. The more cases of inhibition of activation, the higher the likelihood of antiinflammatory and therefore anticancer property.

It is preferred to include as a control, a determination for putative agent on the same cell type as is transfected with construct for testing for inhibition of activation but instead transfected with construct containing Sp1 and reporter gene where activation is carried out using the same activator of transcriptional promoter element as is used in testing in the experimental runs (i.e., not control runs). Sp1 has not been implicated in carcinogenesis or inflammation, and there is not much change in activity when Sp1-containing construct is treated with activator. Thus, any reduction in activity in respect to Sp1-containing construct on treatment with putative agent and inducer will be caused by agents that inhibit reporter (e.g., luciferase) activity or by toxicity of the putative agent and not by inhibiting of transcription factor so that ostensible inhibition of construct containing transcription promoter element implicated in carcinogenesis or inflammation by the same putative agent as causes reduction in activity in respect to Sp1-containing construct, will be shown to be caused by reporter inhibiting activity or by toxicity of the putative agent and not by inhibition of activation by the putative agent. An example of this where the reporter gene is luciferase follows. In a first case, any reduction of luciferase activity of activated construct in cells transfected with construct containing transcriptional promoter element(s) that have been

implicated in carcinogenesis or inflammation, treated with putative agent, is determined compared to luciferase activity of activated construct in cells transfected with construct containing transcriptional promoter element(s) that have been implicated in carcinogenesis or inflammation that have not been treated with the putative agent. In a second case, other cells from the same cell line that provides cells for transfection for said construct are transfected with Sp1 luciferase, and the transfected cells are treated with the putative agent, to determine the extent to which said agent causes reduction in luciferase activity. The result in the second case shows the extent to which reduction in luciferase activity determined for construct containing transcriptional promoter element(s) that have been implicated in carcinogenesis or inflammation is not due to inhibition of activation of transcriptional promoter element(s) by putative agent but rather is due to luciferase activity inhibition or toxicity of the putative agent. Sp1 luciferase construct is commercially available from Promega under the name pGL3 Promoter. The Sp1 sequences in this construct are derived from a portion of the SV40 early region promoter as contained in the pA₁₀CAT construct described in Laimons, L., et al., Proc. Natl. Acad. Sci. U.S.A., 79, 6453-6457 (1982), which is incorporated herein by reference.

The invention is illustrated by the following examples:

Example I

Screening For Drugs Which Suppress
Induction of COX-2

A COX-2 promoter construct was prepared containing 1432 bases 5' of the COX-2 transcription start site (-1432/+59) ligated to luciferase gene.

The plasmid is described in Inoue, H., et al., FEBS Lett., 350, 51-54 (1994). The plasmid is referred to hereinafter as "COX-2 promoter construct."

1483 squamous carcinoma cells (described in Sacks, P. G., et al., Cancer Research, 48, 2858-2866 (1988)) were seeded at a density of 8×10^5 cells/well in six well dishes and grown to 30-40% confluence in DMEM/F-12 containing 10% fetal bovine serum (FBS). For each well, 1.8 μ g of COX-2 promoter construct and 0.2 μ g pCMV.SPORT β gal (from Life Technologies, Inc. of Grand Island, NY) were co-transfected into the 1483 cells using pFx-3 at a 1:12 ratio of DNA to lipid according to the manufacturer's (Invitrogen, San Diego, CA) instructions. After transfection, cells were treated with DMEM/F-12 containing agent being tested (in this case, all-trans-retinoic acid, also referred to herein as ATRA) at a concentration of 1 μ M or vehicle (0.01% DMSO). Twenty-four hours later, the medium was replaced with DMEM/F-12 with or without phorbol 12-myristate 13-acetate (PMA) at 50 ng/ml. The activities of luciferase and β -galactosidase were measured in cellular extract 24 hours later as follows: Each well was washed twice with PBS. Two hundred μ l of 1X lysis buffer (Analytical Luminescence Laboratories, San Diego, CA) was added to each well for 30 minutes. Lysate was centrifuged for 5 minutes at 4 degrees C. The supernatant was used to assay the activities of luciferase and β -galactosidase. Luciferase activity was measured using a Monolight 2010 luminometer (Analytical Luminescence Laboratories) according to the manufacturer's instructions. To measure the activity of β -galactosidase, 40 μ l aliquots of the supernatant were incubated with assay buffer (60 mM Na_2HPO_4 , 1 mM MgSO_4 , 40 mM mercaptoethanol, 10 mM KCl, and 4 mg/ml

O-nitrophenyl- β -D-galactopyranoside) in a total volume of 400 μ l for 30 minutes at 37 degrees C. The reaction was terminated with the addition of 500 μ l of 1M Na₂CO₃, and the absorbance at 420 nm was determined. To adjust for differences in transfection efficiencies, the luciferase values were normalized using β -galactosidase activity. The results are depicted in Fig. 7 of Mestre, J. R., et al., Cancer Research 57, 1081-1085 (1997), which is incorporated herein by reference, wherein the columns represent the mean values and the bars represent the standard deviations. As shown in said Fig. 7, treatment with PMA induced more than a doubling in COX-2 promoter activity and all-trans-retinoic acid suppressed this effect. Comparisons between groups were made by the Students t-test. A difference between groups of $P < 0.05$ was considered significant. The results show all-trans-retinoic acid suppressed PMA induced activation of COX-2 promoter with a difference of $p = 0.01$. These results demonstrate the feasibility of using retinoids to inhibit phorbol ester-mediated activation of COX-2 transcription. The results suggest potential activity for retinoids as anti-cancer and anti-inflammatory agents. The results indicate the efficacy of the invention herein in screening ATRA as a candidate as an anti-cancer and anti-inflammatory drug.

In another case, the construct was the same as that used in this Example above except that the COX-2 promoter ligated to luciferase gene was -1432/+59 and the activator was epidermal growth factor (EGF). Treatment with epidermal growth factor led to approximately a 100% increase in COX-2 promoter activity in the absence of test compounds. This effect was suppressed by all-trans-retinoic acid, 13-cis-retinoic acid, retinyl

acetate, and 9-cis-retinoic acid ($p < 0.001$ compared with EGF treatment). The results are depicted in Fig. 9 of Mestre, J. R., et al., Cancer Research 57, 2890-2895 (1997), which is incorporated herein by reference. In said Fig. 9, the columns represent the mean values and the bars represent the standard deviations.

Example II

Screening for Drugs which Suppress Induction of COX-2 OR MMP

Approximately 800 natural products extracts were screened. Each was screened in a battery of screenings.

Constructs used were COX-2 promoter (-1475/+59) ligated to luciferase, Ets2/AP-1 (described above) ligated to luciferase, NF- κ B ligated to luciferase and Sp1 ligated to luciferase.

The COX-2 promoter-containing construct was prepared similarly to the COX-2 promoter-containing construct used in Example I except -1475/+59 was substituted for -1432/+59.

For the Ets2/AP-1 containing construct, the Ets2/AP1 transcriptional promoter element is that described previously and ligation to luciferase was carried out as follows: Ets2 and AP-1 synthetic DNA oligonucleotides were purchased from Integrated DNA Technologies, Inc., Coralville, Iowa. Each double stranded oligonucleotide contained a 5' BamHI site and a 3' Bgl II site relative to the top strand. The Ets2 element was inserted into the BamHI site and two copies of the AP-1 element were inserted into the Bgl II site of p1A1-LUC in the orientation described above. The luciferase reporter plasmid 1A1-LUC was constructed by inserting a synthetic minimal rat CYP1A1 promoter (bases -1 through -44) 5' to the luciferase gene in

a modified version of the pGL3-Basic Vector (purchased from Promega). The sequence of the rat CYP1A1 gene is found in Sogawa, K., et al., Proc. Natl. Acad. Sci. USA 81, 5066-5070 (1984) which is incorporated herein by reference.

For the NF- κ B containing construct, the NF- κ B transcriptional promoter element is that specifically described above from IgK, and the luciferase construct containing such promoter, pBIIXLUC, was obtained from Dr. Riccardo Dalla-Favera of the Department of Pathology, College of Physicians and Surgeons, Columbia University and is referred to in Chang, C. C., et al., Oncogene 9(3), 923-933 (1994) which is cited above and is incorporated herein by reference.

Sp1 ligated to luciferase (denoted Sp1 hereinafter) for use as a control, was purchased from Promega under the tradename pGL3 Promoter.

The cell line transfected with the constructs to provide transfected cells used herein was human chondrocyte cell line SW1353 having accession no. ATCC HTB 94 and was purchased from the American Type Culture Collection.

Cells from the cell line were transiently transfected by square wave electroporation with each of the constructs as follows: Added into a tube for transfection were 500 μ l DME/F12 medium supplemented with 3% by volume fetal bovine serum, 12×10^6 chondrocyte cells (SW1353) and 25 μ g construct. Square wave electroporation was carried out in a 4 mm electrode cuvette using a T820 Electro Square Porator apparatus obtained from BTX/Genetronics, Inc., San Diego, California. Seventy milliseconds was used for the electroporation time and was selected as being a convenient time. The electroporation voltage used was 150 volts which was the voltage determined by

the procedure for selecting electroporation voltage described above, to provide the best yields of transfected cells for the cell line and constructs being used. The 500 μ l compositions that were subjected to electroporation were diluted into 20 ml of DME/F12 containing 10% fetal bovine serum. The 20 ml of diluted mix was plated into a 96-well plate, 200 μ l per well, to give 0.12×10^6 cells per well (15-18% transfection efficiency). The contents of all the wells was essentially identical. The 96 well cell culture plates used were Cultur Plate (white) from Packard which can be counted directly in the luminometer as described below.

Twenty-four hours after transfection, except in the case of the control and in the case of runs with activator but no agent, the transfected cell compositions were treated with extract of test agent by addition of extract of test agent to wells to provide selected concentration of test agent. The admixtures for all the runs contained 0.1% dimethyl sulfoxide (DMSO). One half hour later, activator (inducer) was added to each well except for the control wells.

The following combinations of construct in transfected cells and inducer were utilized: (1) COX-2 promoter ligated to luciferase as construct and phorbol myristate acetate together with interleukin-1 as inducer; (2) Ets2/AP-1 ligated to luciferase as construct and phorbol myristate acetate as inducer; (3) NF- κ B ligated to luciferase as construct and interleukin-1 as inducer; (4) NF- κ B ligated to luciferase as construct and tumor necrosis factor-alpha as inducer; (5) NF- κ B ligated to luciferase as construct and phorbol myristate acetate as inducer; and (6) Sp1-luciferase as

construct and phorbol myristate acetate together with interleukin-1 inducer.

The phorbol myristate acetate was added to a well to provide a concentration therein of 125 nM. The interleukin-1 was added to a well to provide a concentration therein of 3 ng/ml. The tumor necrosis factor-alpha was added to a well to provide a concentration therein of 50 ng/ml.

Assay for luciferase activity was carried out 7 hours after adding inducer as follows. The contents of a well were aspirated. Directly after aspiration, there was added to a well 40 μ l of a 50/50 mix of Packard LucLite Luciferase reagent and PBS (phosphate buffered saline) containing 1 mM Ca^{++} and 1 mM Mg^{++} . After this, the top of each plate was covered with transparent tape and the covered plate was placed in a Packard TopCount luminometer and the results for each well in the plate were read in light units.

The results for four plant extracts where inhibition activity were determined are set forth in Figs. 1a-1f. The four extracts for which data are shown are hexane extract of *Lycopodium corneum* (denoted "1-F8" hereinafter and in Figs. 1a-1f), hexane/ethyl acetate extract of *Selaginella stellate* (denoted "2-C11" hereinafter and in Figs. 1a-1f), hexane/ethyl acetate extract of *Ambrosia peruviana* (denoted "3-B4" hereinafter and in Figs. 1a-1f), and aqueous extract of *Lithospermum erythrorhizon* (denoted "SUN" hereinafter and in Figs. 1a-1f). Runs were carried out for 1-F8, 2-C11 and 3-B4 at concentrations of 85 and 40 micrograms extract on a dry weight basis (i.e., without solvents) per milliliter which are denoted respectively by "85" and "40" in Figs. 1a-1f. Runs were carried out for SUN at concentrations of 85 and 50 micrograms per milliliter extract on a dry

weight basis (i.e., without solvents) which are denoted respectively by "85" and "50" in Figs. 1a-1f.

Results for combination (1) of construct in transfected cells and inducer are depicted in Fig. 1a. Results for combination (2) of construct in transfected cells and inducer are depicted in Fig. 1b. Results for combination (3) of construct in transfected cells and inducer are depicted in Fig. 1c. Results for combination (4) of construct in transfected cells and inducer are depicted in Fig. 1d. Results for combination (5) of construct in transfected cells and inducer are depicted in Fig. 1e. Results for combination (6) of construct in transfected cells and inducer are depicted in Fig. 1f.

For the runs denoted "CONTROL" in Figs. 1a-1f, no agent or inducer was added but transfected construct was present.

For the runs denoted "INDUCED" in Figs. 1a-1f, no agent was added but transfected construct was present and inducer was added.

The numbers along the vertical axis in each of Figs. 1a-1f are in light units read on The Packard TopCount luminometer wherein greater numbers indicate greater luciferase activity and therefore greater transcriptional promoter activity. In Figs. 1a-1f, the columns represent the average of duplicate values and the bars represent the range.

The results show inhibition of transcriptional activity element by 1-F8 in Figs. 1a-1e and that a significant portion of said inhibition is not due to luciferase activity inhibition or toxicity of 1-F8 (Fig. 1f). The results show inhibition of transcriptional promoter activity by 2-C11 in Figs. 1a-1e and that a significant portion of this inhibition is not due to luciferase activity

inhibition or toxicity of 2-C11 (Fig. 1f). The results show inhibition of transcriptional promoter activity by 3-B4 in Figs. 1a-1e and that a significant portion of this inhibition is not due to luciferase activity inhibition or toxicity of 3-B4. The results show inhibition of transcriptional promoter activity by SUN in Figs. 1a-1e and that a significant portion of this inhibition is not due to luciferase inhibition activity or toxicity of SUN.

The results show that plant extracts 1-F8, 2-C11, 3-B4, and SUN are good candidates for treating inflammation and for preventing or treating cancer.

In another case, runs were carried out the same as above except that the test agent was shikonin, used in a concentration of 3 $\mu\text{g/ml}$, 2 $\mu\text{g/ml}$, 1 $\mu\text{g/ml}$, 0.5 $\mu\text{g/ml}$, or 0.25 $\mu\text{g/ml}$. The results are shown in Figs. 2a-2f where the transfected constructs and inducers were the same for Figs. 1a and 2a, for Figs. 1b and 2b, for Figs. 1c and 2c, for Figs. 1d and 2d, for Figs. 1e and 2e, and for Figs. 1f and 2f. Shikonin is a compound with known antiinflammatory and anti-neoplastic properties. The results for shikonin show that it inhibits activation of the different promoters and by different activators in a manner similar to that shown for SUN. Shikonin is present in SUN extract. The results validate the predictive power of the screen.

Variations will be evident to those skilled in the art. Therefore, the scope of the invention is intended to be defined by the claims.

WHAT IS CLAIMED IS:

1. A method for screening agents as candidates for prophylaxis or treatment of cancer or inflammation, said method comprising (a) providing cells that are transfected with a construct containing transcriptional promotor element(s) that have been implicated in carcinogenesis or inflammation ligated to a reporter gene, and (b) determining whether putative agent inhibits activation of said transcriptional promotor element(s) with a determination of inhibition indicating that the putative agent is a candidate as a drug or as a source of a drug for prophylaxis or treatment of cancer or inflammation.

2. The method of Claim 1 wherein in step (b), the transfected cells are treated with putative agent and with activator of transcriptional promotor activity, the treatment with the putative agent being prior to or simultaneously with the treatment with activator.

3. The method of Claim 2 wherein in step (a), the cells are transiently transfected with the construct.

4. The method of Claim 3 wherein the transient transfection is carried out by electroporation.

5. The method of Claim 4 wherein the transfection is carried out in a medium containing from 2 to 10% by volume fetal bovine serum.

6. The method of Claim 4 wherein in step (a), the reporter gene is luciferase, and in step (b), (i) any reduction of luciferase activity of activated construct in cells transfected with construct treated with putative agent is determined compared to luciferase activity of activated construct in the cells transfected with construct

that are not treated with putative agent, and (ii) other cells from the same cell line as is transfected in step (a) are transfected with Sp1 luciferase and the cells transfected with Sp1 luciferase are treated with the putative agent, to determine the extent to which said agent causes reduction in luciferase activity compared to cells transfected with Sp1 luciferase which are not treated with the putative agent, to determine the extent to which reduction in luciferase activity determined in (i) is due to inhibition of luciferase enzyme activity or toxicity by putative agent.

7. The method of Claim 4 wherein a single electroporation is utilized to transfect cells which are diluted to a volume such as to provide aliquots thereof of the same composition for a plurality of wells for use for determinations, to provide standardization without using normalizing plasmids.

8. The method of Claim 4 wherein a battery of screenings are carried out on a putative agent utilizing in each case cells transfected with a different construct and/or transfected cells activated with a different activator.

AMENDED CLAIMS

[received by the International Bureau on 04 June 1998 (04.06.98);
new claims 9 and 10 added; remaining claims unchanged (1page)]

that are not treated with putative agent, and (ii) other cells from the same cell line as is transfected in step (a) are transfected with Sp1 luciferase and the cells transfected with Sp1 luciferase are treated with the putative agent, to determine the extent to which said agent causes reduction in luciferase activity compared to cells transfected with Sp1 luciferase which are not treated with the putative agent, to determine the extent to which reduction in luciferase activity determined in (i) is due to inhibition of luciferase enzyme activity or toxicity by putative agent.

7. The method of Claim 4 wherein a single electroporation is utilized to transfect cells which are diluted to a volume such as to provide aliquots thereof of the same composition for a plurality of wells for use for determinations, to provide standardization without using normalizing plasmids.

8. The method of Claim 4 wherein a battery of screenings are carried out on a putative agent utilizing in each case cells transfected with a different construct and/or transfected cells activated with a different activator.

9. The method of Claim 1, wherein the said transcriptional promoter element(s) is(are) from the human cyclooxygenase-2 gene.

10. The method of Claim 1, wherein said transcriptional promoter element(s) is(are) from the human stromelysin gene.

AMENDED SHEET (ARTICLE 19)

STATEMENT UNDER ARTICLE 19

The amendments add claims which particularize the transcriptional promoter element(s) of Claim 1 as being from the human cyclooxygenase-2 gene (Claim 9) or from the human stromelysin gene (Claim 10). Such particularization has not heretofore been made in the claims. The amendments have no impact on the description and the drawings.

AMENDED SHEET (ARTICLE 19)




FIG. 1a




FIG. 1b

2/6




FIG. 1c




FIG. 1d

3/6




FIG. 1e




FIG. 1f

4/6




FIG. 2a




FIG. 2b

5/6




FIG. 2c




FIG. 2d

6/6




FIG. 2e




FIG. 2f

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/00023

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) C12Q 1/68; C12N 15/62

US CL 435.6, 172.3, 320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. 435.6, 172.3, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	US 5,556,754 A (SINGER et al) 17 September 1996, columns 16-18.	1, 2 ----- 3-8
X ----- Y	US 5,569,588 A (ASHBY et al) 29 October 1996, columns 2-4.	1, 2 ----- 3-8
Y	US 5,445,941 A (YANG et al) 29 August 1995, columns 10-11 and 16.	3-8

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 MARCH 1998

Date of mailing of the international search report

04 MAY 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CARLA MYERS

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

Printed from Mimosa

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/00023

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS; DIALOG; MEDLINE, CA, DERWENT PATENTS, BIOSIS, EMBASE, SCISEARCH
search terms- screen, identify, reporter, CAT, luciferase, galactosidase, promotor, transcription, activator, inhibitor,
cancer, inflammation

Form PCT/ISA/210 (extra sheet)(July 1992)*

Printed from Mimosa